id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2859704,4e52ff68-c95e-4b9a-afe2-47a05633b422,Q3,"CPPI, CO.",401106160,"CPPI, CO.",2022,third_quarter,PHA,"Advocate in support of personal prescription drug importation from Canada, particularly in the Safe and Affordable Drugs from Canada Act of 2021 (S.259/H.R.832) and the Affordable and Safe Prescription Drug Importation Act (S.920/H.R.2181).","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-10-01T14:46:35-04:00
2859934,ab69e99a-3b41-4f82-901d-8313177abf42,Q3,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2022,third_quarter,PHA,H.R. 7213 - To amend title XVIII of the Social Security Act to provide pharmacy reimbursement for COVID-19-related and future emergency services. S 4293 - Pharmacy Benefit Manager Transparency Act of 2022,"HOUSE OF REPRESENTATIVES,SENATE",,35000,0,0,2022-10-03T11:20:42-04:00
2860083,dd5226f0-7868-4422-930b-72237075335a,Q3,RAY ANDERSON,401105487,340B HEALTH,2022,third_quarter,PHA,Requesting the Secretary of Health and Human Services and HRSA to enforce a statute ordering drug companies to restore 340B discounts to contract pharmacies Requesting Centers for Medicare and Medicaid Services to restore the Medicare hospital Outpatient Prospective Payment System reimbursement rate Requested Representative Spanberger and Representative Danny K. Davis and members of the Congressional Black Caucus participation in a Congressional Special Order Hour session. Gathered CBC member signatures on a Dear Colleague request to Secretary of HHS,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA)",15000,,0,0,2022-10-03T20:23:40-04:00
2860085,463783cc-2dbf-4cab-a3d5-fcda7523925a,Q3,RAY ANDERSON,401105487,340B HEALTH,2022,third_quarter,PHA,Requesting the Secretary of Health and Human Services and HRSA to enforce a statute ordering drug companies to restore 340B discounts to contract pharmacies Requesting Centers for Medicare and Medicaid Services to restore the Medicare hospital Outpatient Prospective Payment System reimbursement rate Requested Representative Spanberger and Representative Danny K. Davis and members of the Congressional Black Caucus participation in a Congressional Special Order Hour session. Gathered CBC member signatures on a Dear Colleague request to Secretary of HHS,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA)",15000,,0,0,2022-10-03T20:23:53-04:00
2860137,62ce50dd-af45-4867-bc35-a83ba596694e,Q3,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2022,third_quarter,PHA,Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.,"HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2022-10-04T10:17:24-04:00
2860598,61149c45-4c8c-41a2-823d-c30e9b4aeba9,Q3,BUCHANAN INGERSOLL & ROONEY PC,55291,AIM IMMUNOTECH INC.,2022,third_quarter,PHA,"Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. FY 2023 Appropriations for Defense Department, and National Institutes of Health (NIH). Work with Department of Defense on Ebola countermeasures.","Defense, Dept of (DOD),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Navy, Dept of,SENATE",20000,,0,0,2022-10-05T10:18:09-04:00
2860981,5433ba6f-5b92-400f-aa62-87d1253795e2,Q3,EQV STRATEGIC,401105663,BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.,2022,third_quarter,PHA,Vaccine Development,"Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE",22500,,0,0,2022-10-06T09:12:32-04:00
2861107,c8347bfd-1b1c-4af5-811e-a8abb980e7f4,Q3,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2022,third_quarter,PHA,"Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program, including the Closing Loopholes for Orphan Drugs Act (H.R. 853).","HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2022-10-06T14:25:04-04:00
2861123,92242fc4-0668-43b8-80a6-4f6d8c844b46,Q3,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,401103605,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,2022,third_quarter,PHA,"COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2022-10-06T15:21:57-04:00
2861519,059eb52b-fb9a-442c-a2e9-1f85eb811139,Q3,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2022,third_quarter,PHA,"PL 117-169 - The Inflation Reduction Act - Support for policies delaying the Trump-era Rebate Rule. S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain. S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work. S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule. S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans. Issues and legislative vehicles related to capping the price of Insulin. Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR). H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule. PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.","HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2022-10-08T09:40:46-04:00
2861528,dbeab2da-c961-475c-8ff5-f24b88983eb6,Q3,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2022,third_quarter,PHA,"PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program. S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-10-08T10:30:52-04:00
2862094,f6a94a7d-a614-4c2e-b3a9-32b8e713bdac,Q3,PENN AVENUE PARTNERS,400918672,"ALKERMES, INC.",2022,third_quarter,PHA,Regulatory and legislative issues impacting Alkermes. S.3593 - Telehealth Extension and Evaluation Act.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-10-10T21:26:28-04:00
2862153,aa7cfdf9-d0d2-4615-b431-e39951ba0ea8,Q3,PENN AVENUE PARTNERS,400918672,"UNITEDHEALTH GROUP, INC.",2022,third_quarter,PHA,Pharmacy benefit related issues.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",90000,,0,0,2022-10-11T08:44:43-04:00
2862271,432ab28c-fbc2-49e4-b87c-28ad393e973a,Q3,POLSINELLI PC,314911,"TEVA PHARMACEUTICALS USA, INC.",2022,third_quarter,PHA,"Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2022-10-11T11:21:42-04:00
2862398,1df8a59f-dd4c-4868-baa4-7581c5ff3878,Q3,"PARDES BIOSCIENCES, INC.",401106493,"PARDES BIOSCIENCES, INC.",2022,third_quarter,PHA,Covid Oral Anti Virals,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE",,120000,0,0,2022-10-11T13:27:31-04:00
2862638,4445d393-c127-46ce-85f6-897e4be983ea,Q3,"BROWN & FORTUNATO, P.C.",401104878,"PROMPTCARE COMPANIES, INC.",2022,third_quarter,PHA,Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators.,Centers For Medicare and Medicaid Services (CMS),20000,,0,0,2022-10-11T16:13:59-04:00
2862886,50fa673b-27cb-41a4-9fbf-b2499e6274cb,Q3,HOLLAND & KNIGHT LLP,18466,VIATRIS INC,2022,third_quarter,PHA,"Drug shortages, formulary tiering, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021 (H.R. 2846), biosimilar uptake, Medicare generics penalty, generic drugs issues, supply chain issues, e-labeling provision in the FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill (H.R. 4356), and Military Construction, Veterans Affairs, and Related Agencies appropriations bill (H.R. 4355), Prescription Drug Pricing Dashboard Act (S. 1773); drug pricing; Build Back Better Act (H.R. 5376); Enhanced Access to Affordable Medicines Act of 2022 (H.R. 6973); Increasing Transparency in Generic Drug Applications Act of 2022 (H.R. 7032); Generic Drug User Fee Amendments.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-12T08:06:21-04:00
2863035,0359ecf0-e4de-4d93-9250-cece2b638b67,Q3,HUMANITY FORWARD,401105867,HUMANITY FORWARD,2022,third_quarter,PHA,Issues and legislation related to reduction of prescription medication for Americans,"HOUSE OF REPRESENTATIVES,SENATE",,250000,0,0,2022-10-12T10:59:02-04:00
2863105,65b54951-9914-4218-8487-0401afd05d4b,Q3,WATKINS & EAGER PLLC,401104403,"ZYNERBA PHARMACEUTICALS, INC.",2022,third_quarter,PHA,Providing services on behalf of Zynerba to the pharmaceutical industry - looking for testing sites,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2022-10-12T11:19:42-04:00
2863312,8ac64f93-f5d0-42ae-a2af-ca076df99907,Q3,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2022,third_quarter,PHA,"IPC supports The Pharmacy Benefit Manager Transparency Act of 2022 IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing IPC supports FTC investigation into vertical PBM arrangements IPC is against decreased pharmacy reimbursement in the TRICARE program IPC is neutral and sought clarifications on the drug pricing provisions of the Inflation Reduction Act of 2022.","Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,30000,0,0,2022-10-12T14:22:59-04:00
2863463,bd1ee63c-91ea-4877-981a-28fa1c83b56f,Q3,THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH,401104060,THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH,2022,third_quarter,PHA,"General education around pharmaceuticals related to Parkinson's disease Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols Prescription Drug User Fee Act H.R. 4417, the Capping Drug Costs for Seniors Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021 S. 2327, the Seniors Prescription Drug Relief Act H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021 H.R. 2163, the Safe Step Act H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act H.R. 5376, the Inflation Reduction Act of 2022","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,31190,0,0,2022-10-12T16:17:58-04:00
2863528,e267c8e8-5487-4d40-98e4-d0854dadbd16,Q3,"BOLD STRATEGIES, LLC",401104653,"MORRIS & DICKSON CO., LLC",2022,third_quarter,PHA,Prescription drug issues generally.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-10-12T16:50:13-04:00
2863621,642f3704-2a82-4f5f-acab-0f1f052cb1a2,Q3,DAVE KOLBE CONSULTING,401104329,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION,2022,third_quarter,PHA,Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization. Waiver of Certain Obligations under the WTO Agreement on Trade Related Aspects of Intellectual Property Rights for COVID-19 to also cover Therapeutics and Diagnostics.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-10-12T19:08:42-04:00
2864065,17e68856-43c8-453c-b5b9-740e99eafd7e,Q3,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2022,third_quarter,PHA,N/A,"HOUSE OF REPRESENTATIVES,SENATE",,60000,0,0,2022-10-13T12:13:40-04:00
2864201,a53d0e2b-1d8d-4b86-8792-65aec052259a,Q3,NELSON MULLINS RILEY & SCARBOROUGH,285871,HEMOPHILIA OF GEORGIA,2022,third_quarter,PHA,"340B Drug Pricing Program, patient co-pay policies","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-10-13T14:10:18-04:00
2864307,9adc5de9-8c5c-4297-aae0-35132e4a7065,Q3,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2022,third_quarter,PHA,"S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; H.R. 7559, Prescription Information Modernization Act; Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services","Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,400000,0,0,2022-10-13T15:10:45-04:00
2864399,9559bc11-2500-45ff-9907-5976693491e0,Q3,NELSON MULLINS RILEY & SCARBOROUGH,285871,TIDELANDS HEALTH,2022,third_quarter,PHA,Issues related to the 340B drug pricing program,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-10-13T15:56:55-04:00
2864566,86512a57-1bfd-4969-a2f6-8b7edb42787e,Q3,ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,58534,ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM,2022,third_quarter,PHA,"Any bill(s), provision(s), or action(s) impacting the 340B Drug Discount Program and hospitals and health systems ability to provide access to these drugs for patients. S.773 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. Any bill(s) or provision(s) addressing high drug prices.","HOUSE OF REPRESENTATIVES,SENATE",,122772,0,0,2022-10-13T17:18:19-04:00
2865039,2d873da6-d539-4e0b-82e4-953540de0686,Q3,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2022,third_quarter,PHA,Monitored Health Data Policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-14T11:22:32-04:00
2865109,83b5ea3b-4d30-43ad-aa1d-2d7c676038c4,Q3,STONINGTON GLOBAL,401105189,"SORRENTO THERAPEUTICS, INC.",2022,third_quarter,PHA,Regulatory approvals and funding for pharmaceutical products and devices,"Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",150000,,0,0,2022-10-14T11:47:11-04:00
2865289,c3994e5a-ca36-4017-8a4a-c5870053eb40,Q3,"DESIMONE CONSULTING, LLC",400931695,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2022,third_quarter,PHA,"Issues related to patient access and pricing; Issues related to policy changes to Medicare Part D; Issues related to PBM reform; PDUFA Reauthorization, H.R.7667, Food and Drug Amendments of 2022, S.4348, FDASLA Act of 2022; FY2022 Budget Reconciliation (H.R.5376); H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-14T12:52:26-04:00
2865298,f1145758-ca4c-4372-a79e-04977b538c61,Q3,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,CHILDREN'S NATIONAL MEDICAL CENTER,2022,third_quarter,PHA,"Representation on health-related issues including reimbursement, research, public-health & clinical care","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2022-10-14T12:54:56-04:00
2865412,fb264656-2931-4604-9feb-6cfa58ddcfe8,Q3,MLJ STRATEGIES,401105126,"ANKURA CONSULTING GROUP, LLC ON BEHALF OF ON DEMAND PHARMACEUTICALS",2022,third_quarter,PHA,Advocating on issues related to pharmaceutical appropriations,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-10-14T13:25:14-04:00
2865421,0598a19f-b57a-444b-bf9e-ca6ef10f0b14,Q3,MLJ STRATEGIES,401105126,"ANKURA CONSULTING GROUP, LLC ON BEHALF OF THORNE RESEARCH",2022,third_quarter,PHA,Advocate on issues related to supplement use in the military,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-10-14T13:28:47-04:00
2865430,7ea02c44-a958-4a18-9181-3bf2c7e26716,Q3,HOGAN LOVELLS US LLP,18422,"ALVOGEN, PHARMA US, INC.",2022,third_quarter,PHA,Issues related to COVID-19,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-10-14T13:35:05-04:00
2865607,860e4f71-6a60-4f85-a9b4-430854008e4a,3T,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,"GLENMARK PHARMACEUTICALS, INC., USA",2022,third_quarter,PHA,"Issues related to affordability, essential medicine manufacturing, and pharmaceuticals. General issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to the Inflation Reduction Act (Public Law 117-169), focusing on pharmaceutical provisions.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,1,2022-10-14T14:46:39-04:00
2865807,96db87e4-6bca-47ca-a57e-21f2625747a4,Q3,LUNGREN LOPINA LLC,401103314,AMPAC FINE CHEMICALS,2022,third_quarter,PHA,Fair treatment for US based pharmaceutical ingredients,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-10-14T15:32:56-04:00
2866137,9b9c251a-af82-4f1b-8d76-d92d0181a33b,3T,"CORNERSTONE GOVERNMENT AFFAIRS, INC.",75557,"VYRIPHARM ENTERPRISES, INC.",2022,third_quarter,PHA,"Policies and regulations associated with testing, tracing and tracking of cannabinoids.","HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE",,,0,1,2022-10-14T22:34:31-04:00
2866151,9ca7defd-fc59-40d6-ada9-91050e272b3a,Q3,ALB SOLUTIONS,401105973,"BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.",2022,third_quarter,PHA,Issues related to regulatory and legislative developments regarding biosimilars.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-10-15T08:19:38-04:00
2866416,aeced5fc-fe24-442a-878b-518cadf57164,Q3,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2022,third_quarter,PHA,Monitoring biotech legislation; prescription drug prices; COVID- Relief legislation; Infrastructure Legislation; FY22 Appropriations bills,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-10-15T14:57:51-04:00
2866925,68e1ec83-88d0-47f0-be87-365d3d88f791,Q3,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2022,third_quarter,PHA,Review of Food and Drug Administrations Final Guidance for industry #256: Compounding Animal Drugs from Bulk Drug Substances Review of Food and Drug Administrations Animal Generic Drug User Fee Act Reports Compounding Guidance (GFI 256) Animal Drug Fee Act/Animal Generic Drug User Fee Act reauthorization,"HOUSE OF REPRESENTATIVES,SENATE",300000,,0,0,2022-10-17T08:28:12-04:00
2867049,9d868664-cffb-49a8-b0be-8fef33180848,Q3,THE CONSILIO GROUP,400374717,PARATEK PHARMACEUTICALS,2022,third_quarter,PHA,"Paratek is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use.","Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office",24000,,0,0,2022-10-17T09:39:03-04:00
2867383,8b0d18c6-7ec9-4d53-ab5d-ecdf205ab4bf,Q3,"BLUESTONE STRATEGIES, LLC",400658980,AMERICA'S HEALTH INSURANCE PLANS (AHIP),2022,third_quarter,PHA,"HR 3, Lower Drug Costs Now Act; HR 5260, Reduced Cost and Continued Care Act; Specialty Drugs and Prescription Drug Pricing, HR 19.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-17T11:08:08-04:00
2867414,2d84e5ab-64ae-4b65-a296-20bf410fffb1,Q3,"BLUESTONE STRATEGIES, LLC",400658980,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2022,third_quarter,PHA,Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-17T11:12:40-04:00
2867421,78a2c646-e6f0-49d2-9ac0-144ff65f7bca,Q3,RICCHETTI INCORPORATED,62778,"EISAI, INC.",2022,third_quarter,PHA,"Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-10-17T11:15:06-04:00
2867477,5f202dd2-5fc7-44e4-a61e-0b421c33aca0,Q3,RICCHETTI INCORPORATED,62778,HORIZON THERAPEUTICS USA INC,2022,third_quarter,PHA,"Issues related to pharmaceutical industry, generally; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2022-10-17T11:23:15-04:00
2867497,a5aebe22-cc6f-4bd4-ac1c-368209ea5ce0,Q3,RICCHETTI INCORPORATED,62778,"IPSEN BIOPHARMACEUTICALS, INC.",2022,third_quarter,PHA,"Issues related to pharmaceutical industry, generally; Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP)","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-10-17T11:27:58-04:00
2867519,06418cdf-dea2-4da3-8839-65125d010963,Q3,RICCHETTI INCORPORATED,62778,"NEUROCRINE BIOSCIENCES, INC.",2022,third_quarter,PHA,"Issues related to pharmaceutical industry, generally","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-10-17T11:30:44-04:00
2867528,deb22d4f-057a-49ad-b3e7-723d3b607948,3T,RICCHETTI INCORPORATED,62778,"PARDES BIOSCIENCES, INC.",2022,third_quarter,PHA,Issues related to government involvement in the development of COVID-19 therapies,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,1,2022-10-17T11:33:30-04:00
2867530,9ae044a4-a1f1-4051-97ce-c636c40129ba,Q3,RICCHETTI INCORPORATED,62778,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2022,third_quarter,PHA,"Issues related to pharmaceutical industry, generally","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-17T11:34:47-04:00
2867546,a249dbbb-734c-4ff7-a51a-30566e932037,Q3,FORBES-TATE,400976792,CALIFORNIA LIFE SCIENCES ASSOCIATION,2022,third_quarter,PHA,Issues related to the life sciences industry; Issues related to drug pricing; Issues related to H.R. 5376 - Inflation Reduction Act of 2022(P.L. 117-169).,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-10-17T11:37:51-04:00
2868006,9e5e5525-3e4c-4754-90c4-80510423b720,Q3,CHRISTIANACARE,401105790,CHRISTIANACARE,2022,third_quarter,PHA,"Specific lobbying issues: Issues related to the 340B Program, in general House(s) of Congress and Federal Agencies","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-10-17T13:13:17-04:00
2868310,e5aed995-078d-4877-8571-246aa852f00d,Q3,FORBES-TATE,400976792,INDEPENDENT PHARMACY COOPERATIVE,2022,third_quarter,PHA,"Issues related to pharmacy regulation, the MAC Transparency Act, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-17T14:30:21-04:00
2868663,2f570d0b-4357-42d5-ae61-3bb40545b4a0,Q3,"GOVERNMENT COUNSEL, LLC",401105070,HEALTHCARE DISTRIBUTION ALLIANCE,2022,third_quarter,PHA,General issues related to opioid medication assisted treatment.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-17T15:27:08-04:00
2868671,baf14b24-c641-4886-adc7-938857669cbc,Q3,THE D MAJOR GROUP,401103162,"EMD SERONO, INC.",2022,third_quarter,PHA,"Monitor FDA User Fee Reauthorization measures as included in HR 6833, the ""Continuing Appropriations & Ukraine Supplemental Appropriations Act.""","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-10-17T15:29:25-04:00
2869246,7f589831-3a8c-4d9f-ac1b-8e4fba9ad593,Q3,OREGON HEALTH & SCIENCE UNIVERSITY,30291,OREGON HEALTH & SCIENCE UNIVERSITY,2022,third_quarter,PHA,Support for the 340B Drug Discount Program for safety net hospitals and enforcing the Health Resources and Services Administration's statute governing the program.,"HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2022-10-17T17:22:54-04:00
2869290,e2a75fd5-74af-414d-9d03-5b8796477631,Q3,WEST FRONT STRATEGIES LLC,401103493,VIATRIS INC,2022,third_quarter,PHA,Issues related to e-labeling; monitor issues related to Pharmacy Benefit Manager Transparency Act of 2022 (S.4293).,"HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2022-10-17T17:41:20-04:00
2869313,c19ebd7a-203f-4a56-aab0-8b794c28ca5a,Q3,KNIGHT CAPITOL CONSULTANTS,40036301,REGENXBIO,2022,third_quarter,PHA,Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill),SENATE,60000,,0,0,2022-10-17T17:55:53-04:00
2869509,c563b717-00ea-42f9-8dc2-fd66a814db78,Q3,BROYDRICK & ASSOCIATES,7268,TONIX PHARMACEUTICALS,2022,third_quarter,PHA,Funding new drug for PTSD and COVID-19. BARDA appropriations.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-10-17T20:08:34-04:00
2869520,80fcba75-5441-4dc2-89e2-b0c77fcd7245,Q3,"PORT SIDE STRATEGIES, LLC",401105394,NEW VENTURE FUND,2022,third_quarter,PHA,H.R.8289 - Banning Misleading Drug Ads Act of 2022 - in support.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-10-17T20:12:04-04:00
2869714,b450a307-2abd-402f-a65b-ad1fcb8918e9,Q3,CAPITOL COUNSEL LLC,313715,"EMD SERONO, INC.",2022,third_quarter,PHA,Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-10-17T21:58:36-04:00
2869849,b728ea23-bbb5-4148-951b-9ec263292387,Q3,ACG ADVOCACY,2057,WALGREEN CO.,2022,third_quarter,PHA,Drug Pricing Policy Issues. Data privacy and DIR fee reform. Counterfeiting Issues.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-10-18T02:08:48-04:00
2870180,f4bc27cb-ed05-458d-82b9-b05fc8a8e4b2,Q3,PUBLIC CITIZEN,32362,PUBLIC CITIZEN,2022,third_quarter,PHA,"Drug price patent licensing executive action, INSULIN act, Licensing Government owned COVID technologies, Exercising executive licensing authorities to lower drug prices, HR 7900-NDAA amendment on Public protection of insulin for DOD, reconciliation drug price reform, and drug price negotiation provisions, Executive action to expand monkey pox Vaccine access, Global Covid 19 funding, HR 5376-Inflation reduction Act-drug pricing reform, insulin and drug price negotiation provisions, global and domestic monkey pox funding, Prescription Drugs affordability and access act, We PAID Act, USG support for mRNA hub","HOUSE OF REPRESENTATIVES,SENATE,White House Office",,70000,0,0,2022-10-18T10:10:22-04:00
2870673,94c9d495-6eb5-4fbf-8b62-93be577a08fb,Q3,PRIME POLICY GROUP,400532589,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2022,third_quarter,PHA,H.R. 7213 - Equitable Community Access to Pharmacist Services Act; Vaccines for Uninsured Adults Initiative,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-18T11:39:25-04:00
2870699,abe2ff51-a482-40ae-b132-5d636591f092,Q3,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2022,third_quarter,PHA,"340B, white bagging, PDUFA","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,32090,0,0,2022-10-18T11:42:02-04:00
2870861,fe8d01eb-f08a-42d1-90fa-7ce174a4518d,Q3,ARENTFOX SCHIFF LLP,4208,"AMERICAN PHARMACY COOPERATIVE, INC.",2022,third_quarter,PHA,"Prescription drug pricing generally S. 4293 (Pharmacy Benefit Manager Transparency Act of 2022), regarding prescription drug pricing","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-10-18T12:11:35-04:00
2870918,5eceb23a-a362-42aa-8b98-74443299a88a,Q3,KING & SPALDING LLP,21632,"SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.)",2022,third_quarter,PHA,Advocacy on low income subsidy benefits,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-18T12:16:05-04:00
2871175,9af693e1-c562-4b1d-a880-ad0d3fa9f356,Q3,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2022,third_quarter,PHA,Hospital discounts; 340B program; Affordable Prescriptions for Patients Act of 2021 (S.1435),"HOUSE OF REPRESENTATIVES,SENATE",,1210000,0,0,2022-10-18T13:01:58-04:00
2871525,529f0521-b25f-477e-955c-50528aa1f85b,Q3,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2022,third_quarter,PHA,"OTC switch process -- no bill number H.R. 6000 - 21st Century Cures 2.0 S.1435/HR 2873 - Affordable Prescriptions for Patients Act of 2021 H.R.4405 - Small Business FDA User Fee Adjustment Act of 2021 H.R. 7667 - Food and Drug Amendments of 2022 Dietary Supplement Reform -- no bill number Cosmetics Reform -- no bill number S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 or the FDASLA Act of 2022 Genus vs. FDA Circuit Court Lobby Activity S. 4535 - Food and Drug Administration Simple Reauthorization Act of 2022 or the ""FDASRA Act of 2022"" H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,142000,0,0,2022-10-18T14:02:15-04:00
2871859,ce4ba80b-6819-4da7-a33f-4c122284d93b,Q3,LINCOLN PARK GROUP L.L.C.,401104374,CANADIAN INTERNATIONAL PHARMACY ASSOCIATION,2022,third_quarter,PHA,"Support for S. 920/H.R. 2181 - A bill to amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals and S. 259/H.R. 832 - Safe and Affordable Drugs from Canada Act; S. 3399/H.R. 6532 Domain Reform for Unlawful Drug Sellers Act; S. 3984, Stop Illegal Online Sales of Controlled Substances Act; and other issues related to personal drug importation.","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2022-10-18T15:00:58-04:00
2872099,3f8c27b2-5cef-444c-b1f8-e149c35b2551,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN),2022,third_quarter,PHA,"Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in user fees legislation.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-18T15:25:45-04:00
2872129,85d18e51-2716-4e7f-8b6d-6fe3ed540339,Q3,SQUIRE PATTON BOGGS,30906,"SK HYNIX AMERICA, INC.",2022,third_quarter,PHA,Monitor proposals and issues related to biopharmaceuticals.,"HOUSE OF REPRESENTATIVES,SENATE",170000,,0,0,2022-10-18T15:29:34-04:00
2872153,6df5a43e-f8ed-47af-9401-614f340a6d05,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION),2022,third_quarter,PHA,"Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to Monkeypox vaccine and treatment distribution. Issues related to drug pricing in the Inflation Reduction Act (Public Law 117-169).","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-18T15:33:04-04:00
2872188,c248b367-d2ee-43c2-ac9d-f1487923b65b,Q3,DENTONS US LLP,36105,PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA,2022,third_quarter,PHA,Federal issues impacting workforce and innovation in the pharmaceutical industry.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-10-18T15:38:07-04:00
2872345,7c520daf-77ff-4cb1-8f97-3c19fcd6e838,Q3,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2022,third_quarter,PHA,General issues related to over-the-counter pharmaceutical supply chain. Issues related to dietary supplements and cosmetic reform in the user fees reauthorization legislation.,,50000,,0,0,2022-10-18T15:59:36-04:00
2873345,441ca408-2937-421c-8fb9-831dec577a5f,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,MEDIVANT HEALTHCARE,2022,third_quarter,PHA,Issues related to pharmaceutical manufacturing and supply,,,,0,0,2022-10-18T20:00:07-04:00
2873353,eb3e7bc2-9773-4ce8-bc0e-05c1c7b72b4f,Q3,"BROWNSTEIN HYATT FARBER SCHRECK, LLP",7257,"LILLY USA, LLC",2022,third_quarter,PHA,Issues related to the pharmaceutical industry H.R. 5376 - Inflation Reduction Act,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-18T20:20:57-04:00
2873527,4db60422-db60-46f4-8c1f-1856ed7388e5,Q3,THE KPM GROUP DC LLC,401105372,"CHIESI USA, INC.",2022,third_quarter,PHA,"S. 4348 - FDASLA Act of 2022 H.R. 7667 - Food and Drug Amendments of 2022 H.R. 5376, the Inflation Reduction Act of 2022 Public Law 97-414, the Orphan Drug Act","HOUSE OF REPRESENTATIVES,SENATE,White House Office",30000,,0,0,2022-10-18T23:41:13-04:00
2873537,21c64ace-88e1-4857-9a68-0af1fdd7703d,Q3,THE KPM GROUP DC LLC,401105372,OVID THERAPEUTICS,2022,third_quarter,PHA,"H.R. 5376, the Inflation Reduction Act of 2022 H.R. 4436, the Daniel Anderl Judicial Security and Privacy Act of 2021","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-10-18T23:46:34-04:00
2873539,bf09a569-d2b1-4ea0-991b-95b1481e6bb3,Q3,THE KPM GROUP DC LLC,401105372,RARE DISEASE COMPANY COALITION,2022,third_quarter,PHA,"S. 4348, the FDASLA Act of 2022 H.R. 7667, the Food and Drug Amendments of 2022 H.R. 5376, the Inflation Reduction Act of 2022 Public Law 97-414, the Orphan Drug Act","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-18T23:48:19-04:00
2873542,8f79e0b8-bbc3-421b-812e-bc0796602972,Q3,THE KPM GROUP DC LLC,401105372,STEALTH BIOTHERAPEUTICS INC.,2022,third_quarter,PHA,Orphan drug incentives,"SENATE,White House Office",30000,,0,0,2022-10-18T23:52:13-04:00
2873843,123900dc-cb51-45f2-858f-fcfc559f4fcc,Q3,VAN SCOYOC ASSOCIATES,39837,ZEBRA TECHNOLOGIES CORP.,2022,third_quarter,PHA,"H.R.7900/S.4543, National Defense Authorization Act for Fiscal Year 2023, Temperature monitoring technology, Rapid Diagnostic Test Kits S.3799, PREVENT Pandemics Act, Rapid Diagnostic Test related issues","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-10-19T08:46:56-04:00
2874458,d3b37b8b-1845-4c1f-b6de-53f92e0549a1,Q3,FAEGRE DRINKER BIDDLE & REATH LLP,12631,"VERDE ENVIRONMENTAL TECHNOLOGIES, INC.",2022,third_quarter,PHA,Drug safety.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",20000,,0,0,2022-10-19T10:21:05-04:00
2874472,8d091606-ebb4-4eed-879e-2c5579c18214,Q3,"CARD & ASSOCIATES, LLC",84217,AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY),2022,third_quarter,PHA,Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitoring federal appropriations for FY 2023 Access to telehealth Healthcare Extenders,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2022-10-19T10:23:08-04:00
2874529,cb22e4fe-e598-4ddf-b15b-2c295dd0297e,Q3,FAEGRE DRINKER BIDDLE & REATH LLP,12631,NATIONAL ASSOCIATION OF BOARDS OF PHARMACY,2022,third_quarter,PHA,"Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act; S. 2796/H.R. 2985 Rural Opioid Abuse Prevention Act; H.R. 2355 Opioid Prescription Verification Act.","Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE",30000,,0,0,2022-10-19T10:30:30-04:00
2875053,445d6612-51cb-4b25-a855-68f6eca75988,Q3,RAMPY NORTHRUP LLC,401103289,ASTRAZENECA PHARMACEUTICALS LP,2022,third_quarter,PHA,"Provide legislative and regulatory advice related to vaccine development, drug pricing, the 340B Drug Pricing Program, PDUFA Reauthorization, and clinical trial diversity; H.R.6000, Cures 2.0 Act; FY2022 Budget Reconciliation/Inflation Reduction Act of 2022 (H.R.5376, P.L.117-169); H.R.5585, Advanced Research Project Agency-Health Act; H.R.5030/S.2706, DIVERSE Trials Act; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180); H.R.7559, Prescription Information Modernization Act of 2022; H.R.2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021.",HOUSE OF REPRESENTATIVES,60000,,0,0,2022-10-19T11:15:26-04:00
2875085,75aea893-97d4-4593-9877-623d916c88f5,Q3,BURRELL INTERNATIONAL GROUP LLC,401103483,ACER THERAPEUTICS,2022,third_quarter,PHA,"COVID 19 therapeutics and Medical Countermeasures, Rare Disease and Re-purposed drugs; - FY22 Defense Appropriations for MCM Development","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-10-19T11:17:52-04:00
2875215,d5d4c8cb-ba4f-47d3-99fc-1b1b324f68de,Q3,AARP,1694,AARP,2022,third_quarter,PHA,"P.L. 117-169, Inflation Reduction Act. S.4430, the Interagency Patent Coordination and Improvement Act of 2022. No bill number. Discussed allowing one time change in Medicare Part D plans. No bill number. Discussed cancer drug launch prices.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,4790000,0,0,2022-10-19T11:31:49-04:00
2875245,84e1e8d3-6865-4680-ae62-b99354d59923,Q3,BURRELL INTERNATIONAL GROUP LLC,401103483,TONIX PHARMACEUTICALS HOLDING CORP.,2022,third_quarter,PHA,R&D Funding for Tonix Products and Services,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2022-10-19T11:34:11-04:00
2875609,375ea8bf-4e49-48eb-bb96-c91d6ac4c9cf,Q3,"BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.",6382,BLUE CROSS AND BLUE SHIELD OF FLORIDA INC,2022,third_quarter,PHA,"COVID-19 Testing; Prescription Drugs; Insulin; Coverage of COVID-19 Testing and Vaccines HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees. The Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, by Sen. Jeanne Shaheen (D-NH) and Sen. Susan Collins (R-ME). Increases measures to encourage insulin manufacturers to reduce list prices, while extending patient protections that will foster competition and broader access to insulin products.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,130000,0,0,2022-10-19T12:09:29-04:00
2875653,bb3e3ea2-a2d8-4e7f-b294-6b5306cb4985,Q3,GUIDEWELL MUTUAL HOLDING CORPORATION,401103191,GUIDEWELL MUTUAL HOLDING CORPORATION,2022,third_quarter,PHA,"COVID-19 Testing; Prescription Drugs; Insulin; Coverage of COVID-19 Testing and Vaccines HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees. The Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act, by Sen. Jeanne Shaheen (D-NH) and Sen. Susan Collins (R-ME). Increases measures to encourage insulin manufacturers to reduce list prices, while extending patient protections that will foster competition and broader access to insulin products.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,,0,0,2022-10-19T12:13:43-04:00
2875761,4363dd4e-ea8f-403d-9a52-11bc93fda5f7,Q3,GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS),400270236,GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS),2022,third_quarter,PHA,PBM Drug Pricing Legislation,"HOUSE OF REPRESENTATIVES,SENATE",,146000,0,0,2022-10-19T12:23:34-04:00
2875811,480cbf46-500e-4d32-8b69-075f0ce49e72,Q3,GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS),400270236,GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS),2022,third_quarter,PHA,PBM Drug Pricing Legislation,"HOUSE OF REPRESENTATIVES,SENATE",,146000,0,0,2022-10-19T12:26:29-04:00
2876198,fe3a5ca7-62a8-4d94-a736-b07f33f31116,Q3,"ALBERTSONS COMPANIES, INC.",401106186,"ALBERTSONS COMPANIES, INC.",2022,third_quarter,PHA,"Issues related to workforce, pharmacy services, nutrition and food production, processing and labeling.","HOUSE OF REPRESENTATIVES,SENATE",,410000,0,0,2022-10-19T12:46:01-04:00
2876231,14ae9924-11ba-4bb2-8f01-0f99d76d96fe,Q3,BUCHANAN INGERSOLL & ROONEY PC,55291,ALLAY THERAPEUTICS,2022,third_quarter,PHA,Develop and execute a government relations strategy relating to Allay Therapeutics agenda and new drug application (NDA).,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2022-10-19T12:48:30-04:00
2876305,fcd7d6d6-c578-4fa8-b0a9-9b67ea709342,Q3,BUCHANAN INGERSOLL & ROONEY PC,55291,"FERA PHARMACEUTICALS, LLC",2022,third_quarter,PHA,Strategy development and implementation of federal government relations initiatives relating to phospholine iodide issues with the Food and Drug Administration and Centers for Medicare and Medicaid Services.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2022-10-19T12:54:30-04:00
2876363,5588bb43-0f53-48a6-a19d-5190d217f840,Q3,BUCHANAN INGERSOLL & ROONEY PC,55291,GENERIC ANIMAL DRUG ALLIANCE,2022,third_quarter,PHA,"Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 8857, the Generic Animal Drug Advancement Act, all provisions","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2022-10-19T12:58:30-04:00
2876445,e8f0fa77-18ca-4e0e-bb06-cf7dbc10e81f,Q3,"AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES",2321,AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES,2022,third_quarter,PHA,Lower Prescription Drug Prices,SENATE,,470000,0,0,2022-10-19T13:02:47-04:00
2876569,010fcfde-97fb-4657-9e08-04f645128d58,Q3,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2022,third_quarter,PHA,"Opioid abuse - general issues related to opioid abuse and access to medication assisted treatment; issues related to ARCOS data and suspicious order record requirements and reporting HR 768 Block, Report, and Suspended Suspicious Shipments Act of 2021 Importation of Prescription Drugs (HR 832, HR 2181, S 259, S 920, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA)","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2022-10-19T13:17:56-04:00
2876763,f8f34c3e-8c66-4d5f-98aa-4e10c8c6eaa5,Q3,"MEHLMAN CONSULTING, INC.",284950,"MARIPOSA HEALTH, INC. (ON BEHALF OF PLUME)",2022,third_quarter,PHA,Issues related to tele-health. Ryan Haight Act.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2022-10-19T13:32:20-04:00